Send to

Choose Destination
Clin Rheumatol. 2018 Sep;37(9):2361-2366. doi: 10.1007/s10067-018-4159-2. Epub 2018 Jun 1.

Serological lymphocytic activity and patient-reported outcomes in Sjögren's syndrome.

Author information

Department of Rheumatology and Clinical Immunology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Department of Pneumology, Rheumatology, and Nephrology, RoMed Medical Centre, Pettenkoferstr. 10, 83022, Rosenheim, Germany.
Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Freiburgerstrasse 10, 3010, Bern, Switzerland.


This study was set to investigate whether serum markers of lymphocytic activity are associated with patient-reported outcomes in Sjögren's syndrome (SS). Forty-six patients with SS were included in this cross-sectional study. Patients with monoclonal gammopathy, history of malignant lymphoma, or with secondary SS were excluded. Serum levels of IgG, β2-microglobulin (β2M), soluble interleukin-2 receptor (sIL2-R), and free light chains (FLC) were assessed. Systemic disease activity was measured by the EULAR SS disease activity index (ESSDAI). Patient-reported symptoms were recorded by visual analogue scales (VAS) of pain, fatigue, and dryness, as compiled in the EULAR SS patient-reported index (ESSPRI). Depressive symptoms were determined by the Patient Health Questionnaire 9 (PHQ-9). Serum concentrations of κFLC (r = 0.491, p = 0.001), λFLC (r = 0.326, p = 0.027), and β2M (r = 0.421, p = 0.004) correlated with the ESSDAI, whereas sIL-2R and IgG did not. No correlations between serum markers of lymphocytic activity and the ESSPRI, or single VAS measures of pain, dryness, or fatigue, were found. In patients with VAS fatigue scores in the upper quartile, sIL-2R serum levels were even decreased (p = 0.019). Only depressive symptoms as determined by PHQ-9 were positively correlated with fatigue (r = 0.536, p < 0.001). In this well-defined cohort of patients with SS, serological lymphocytic activity was not correlated with patient-reported outcomes and sIL-2R levels were even decreased in patients with high fatigue scores. Only depressive symptoms were correlated with fatigue. This highlights the need to further understand the link between inflammation and disease characteristics in SS.


ESSDAI; ESSPRI; FLC; Free light chains; IgG; Immunoglobulin G; PHQ-9; Sjögren’s syndrome; Soluble interleukin-2 receptor; sIL-2R; β2-microglobulin


Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center